NCT00768651
Incretin Effect and Use After Clinical Islet Transplantation
See it on ClinicalTrials.gov ↗8 people
12.5%
87.5%
1 womenmiddle line = equal numbers7 men
- Phase
- PHASE2
- Paid for by
- University of Alberta
- Finished
- 2011-12
- Health conditions
- Type 1 Diabetes
- Who could join
- Anyone
- Ages
- 18 Years – 70 Years
- Average age
- median 54 years
- Age 65+
- Not reported
- Weight (BMI)
- mean 22.6 kg/m^2
- Pregnancy recorded
- Not reported
- Menopause recorded
- Not reported
- Results shown by sex
- Not split by sex
- Race
- Not reported
Women left out
- No pregnant women
Women who were pregnant could not join.
“Vulnerable populations (i.e. cognitively impaired, pregnant women, residing in institutions, University of Alberta students or employees under the supervision of any of the investigators).”
- No kidney or liver problems
Women with kidney or liver problems were turned away.
“Renal disease or renal dysfunction (as suggested by serum creatinine levels ≥ 136 µmol/L (males), ≥ 124 µmol/L (females) or abnormal creatinine clearance; or estimated by Glomerular Filtration Rate (GFR) \<50 ml/min/1.73m2).”
- No diabetes
Women with diabetes were turned away.
“Acute or chronic metabolic acidosis with or without coma (including diabetic ketoacidosis).”
Study titles and rules are shown in their original English.